{"title": "2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 37", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come", "hostname": "fiercepharma.com", "description": "After an average of 51 new drug approvals per year since 2017, the FDA logged only 37 in 2022. Has the regulator become gun-shy after having to walk back its controversial 2021 blessing of Biogen's Alzheimer's disease treatment Aduhelm? | Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2022, however, fewer drugs were approved than was typical in recent years. Is this the result of the FDA becoming gun-shy after its much-criticized sanction of Biogen's Alzheimer's disease treatment, Aduhelm, in 2021? Or was 2022 just a cyclical blip on the approval landscape?", "sitename": "FiercePharma", "date": "2023-01-03", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}